Contraceptive Technology Update
RSSArticles
-
Herpes Vaccine Research May Be Propelled Toward Possible Candidate
Researchers have designed a new type of vaccine that could be the first for preventing genital herpes. By using a counterintuitive scientific approach, scientists were able to prevent active and latent infections caused by herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes.
-
Help young women transition to adult healthcare
Young women ages 18 to 25 represent a heterogeneous population transitioning from adolescence into adulthood who might present with unique issues and challenges, including a potential gap in healthcare after pediatric healthcare. The American College of Obstetrics and Gynecology has just released a committee opinion to help providers structure preventive healthcare visits to screen for health issues and counsel patients about a variety of health topics, including reproductive health.
-
Counsel women on how to cope with menopause’s vasomotor symptoms
New research indicates that frequent vasomotor symptoms associated with menopause could last more than seven years for many women.
-
How to get the message across to young men about using condoms consistently and correctly
When used consistently and correctly, latex condoms are effective at preventing sexually transmitted infections, including HIV.
-
Research eyes effect of body weight and BMI impact on emergency contraception
Results of a new statistical analysis of clinical data suggest a significant drop in the efficacy of levonorgestrel emergency contraceptive pills with increasing body weight.
-
Intrauterine device and implant are effective beyond use approved by the FDA
An initial analysis of data conducted by Washington University School of Medicine in St. Louis indicates that hormonal intrauterine devices and contraceptive implants remain highly effective one year beyond their approved duration of use.
-
Options Expand for Women: FDA Approves a New Intrauterine Device
A new option in intrauterine contraception has been approved: the LILETTA intrauterine device.
-
HPV screening: Option to cytology-based options
Primary human papillomavirus (HPV) screening can be considered as an alternative to current U.S. cytology-based cervical cancer screening methods, according to new interim guidance from the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology.1
-
Data reaffirm the effectiveness of LNG, copper intrauterine devices
Findings from a recent analysis of data from a large, multi-country study of women using levonorgestrel or copper intrauterine devices (IUDs) indicate that while both forms of contraception have high levels of efficacy, the levonorgestrel device daily releasing 20 mcg (Mirena LNG IUD, Bayer Healthcare Pharmaceuticals, Wayne, NJ) was associated with a significantly lower risk of pregnancy, including ectopic pregnancy, than copper IUDs.1
-
New HPV vaccine covers 9 types of HPV
Get ready to include a new human papillomavirus (HPV) vaccine at your facility. The Food and Drug Administration (FDA) has approved Gardasil 9 from Kenilworth, NJ-based Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.